<DOC>
	<DOCNO>NCT02476539</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability pharmacokinetics Hemay022 . The secondary purpose study assess efficacy Hemay022 treatment HER2-positive advance breast cancer . The study conduct two part . Part one , trial conduct 18-30 subject determine safety tolerability Hemay022 patient HER2-positive advance breast cancer . Part two , approximately 27 additional subject HER2-positive advanced breast cancer , include good define tolerability preliminary efficacy Hemay022 .</brief_summary>
	<brief_title>Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer</brief_title>
	<detailed_description>This phaseⅠsequential-group study ascend single multiple oral dos administer subject HER2-Positive Advanced Breast Cancer . Each subject receive single dose Hemay022 , follow 1-week observation period , receive Hemay022 administer daily mouth 28 day . Each cycle consist 28 day . Subjects enrol group 3 6 . Depending safety activity profile observe dose escalation phase , dose select Part 2 may adjust . Part 2 extension part three dose group .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Male female subject age 18 65 year ; 2 . Histologically cytologically confirm radiologically diagnose advanced breast cancer subject ; subject fail standard therapy，or effective therapy available subject 3 . HER2 overexpression IHC score 3+ , 2+ FISH confirmation ; 4 . Preferably measurable tumour lesion define RECIST criteria1.1 ; 5 . Subjects receive chemotherapy least 4 week prior screen ( least 6 week washout time frame treat mitomycin nitrosoureas ) must recover toxic effect treatment CTCAE 4.03≤ Grade 1 ; 6 . ECOG Performance Status 0,1 ; 7 . Life expectancy least three month ; 8 . Adequate bone marrow , liver , kidney function , meet follow creteria : ANC≥1.5×109/L , HB≥90g/L , PLT≥75×109/L； TBIL≤1.5×ULN , ALT≤1.5×ULN , AST≤1.5×ULN ; Cr ≤1×ULN ; BUN ≤1×ULN ; 9 . Left ventricular ejection fraction ( LVEF ) ≧50 % measure Ultrasonic cardiogram ( UCG ) 10 . All female male subject must agree commit use reliable contraceptive regimen duration study least 12 week last dose test article . Female subject must negative serum urine pregnancy test perform within 7 day prior treatment ; 11 . Ability understand willingness sign write informed consent study entry ; 12. subject would good communication investigator could comply protocol 1 . Patients parenteral nutrition ; malabsorption syndrome ; condition possibly affect drug absorption inability tolerate oral medication ; 2 . Clinically QTc prolongation , ventricular tachycardia , ventricular fibrillation , heart block , myocardial infarction within 1 year , congestive heart failure , symptom require medicine treatment patient coronary heart disease ; 3 . Ventricular ejection fraction ( LVEF ) &lt; 50％ ; 4 . Active infection ( ie , require intravenous antibiotic antiviral agent ) ; 5 . Active central nervous system metastases 6 . Have receive clinical trial treatment within 4 week prior study ; 7 . Have receive target therapy within 4 week prior study ; 8 . Pregnant breast feeding woman ; 9 . Have know hypersensitivity test article excipient test article ; 10 . Evidence significant medical illness abnormal laboratory find would make subject inappropriate study investigator 's judgment . 11 . Subjects complete study due reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>